Clinical trials: Behavioural Disorder
Attention Deficit Hyperactivity Disorder (ADHD)
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
The purpose of this research study is to learn about the effects of a medication called Vyvanse on the heart (cardiovascular system). The U.S.
- Trial name
- NCT00753012
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
This is PART A of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03265119
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Disorder
Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
The study hypothesis is that DHA is more effective than placebo in increasing brain activation and reducing symptoms in psychostimulant-free children with ADHD.
- Trial name
- NCT01883817
- Testing
- DHA Omega-3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Smoking Cessation, Electronic Cigarette Use
Cessation of Smoking Trial in the Emergency Department
The Cessation of Smoking Trial in the Emergency Department (CoSTED) is an National Institute for Health Research (NIHR) Health Technology Assessment (HTA) funded randomised controlled trial (RCT).
- Conditions
- Smoking Cessation, Electronic Cigarette Use, E-Cig Use, Vaping
- Trial name
- COSTED (NCT04854616)
- Testing
- CoSTED Intervention
- Where
- United Kingdom
- Volunteers
- 972 people, healthy volunteers welcome
- Sponsor
- Norfolk and Norwich University Hospitals NHS Foundation Trust
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Child Behavior Disorders
The Inner Garden and Care for Children With Moderate to Severe Agitation
The objective is to compare the care including the solution of ambient sensory biofeedback "Inner Garden", compared to the care without this solution, on the regulation of behavioral disorders during a crisis requiring to take…
- Trial name
- ESSAIMS (NCT04610281)
- Testing
- Inner Garden
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Attention-Deficit/Hyperactivity Disorder
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT02163915
- Testing
- TAK-137
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Takeda
ADHD
Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD
This work will assess the prevalence in hard-to-treat ADHD of the ineffectiveness of the anesthetic Lidocaine.
- Trial name
- NCT04167189
- Testing
- Lidocaine gel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- PhenoSolve, LLC
Adult Attention Deficit Hyperactivity Disorder (ADHD)
Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD
The purpose of this study is to evaluate the effectiveness and safety of Daytrana® in the treatment of attention deficit hyperactivity disorder (ADHD) in adults who have abused stimulants in the past.
- Trial name
- NCT00780208
- Testing
- Daytrana (methylphenidate patch)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Medical University of South Carolina
Traumatic Brain Injury, Attention Deficit Disorder
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can help with attention deficits due to traumatic brain injury (TBI).
- Trial name
- NCT01000064
- Testing
- Vyvanse, fMRI
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University
Attention Deficit Hyperactivity Disorder
New Technologies to Help Manage ADHD
Cluster randomized controlled trial to evaluate the general effectiveness of intervention compared to control on medication continuity as measured by prescriptions written and other more proximal outcomes during the first six…
- Trial name
- NCT02390791
- Testing
- enhanced myADHDportal.com, treatment as usual standard portal
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder (ADHD)
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12…
- Trial name
- NCT01835548
- Testing
- NT0102
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Neos Therapeutics, Inc
Mood Disorder, Mental Disorder Diagnosed in Childhood
A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
Severe mood dysregulation (SMD) is a very common syndrome in children. Its symptoms include very severe irritability, including persistent anger and frequent outbursts, as well as distractibility, hyperactivity, and other…
- Conditions
- Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT00794040
- Testing
- Add-on citalopram following optimized methylphenidate
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Mental Health (NIMH)
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at 6.25 milligram (mg) in children aged 4 to 12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03325894
- Testing
- SHP465
- Where
- 48 sites in United States
- Volunteers
- 141 people
- Sponsor
- Shire
Conduct Disorder, Oppositional Defiant Disorder
Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits
The purpose of this study is to modify behavior therapy so that it is optimized for children with conduct problems and callous-unemotional traits by emphasizing reward components and de-emphasizing punishment components.
- Trial name
- NCT01362946
- Testing
- Reward-Emphasized Treatment, Standard Treatment
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Florida International University
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.
- Trial name
- NCT00626236
- Testing
- SPN-810
- Where
- 9 sites in United States
- Volunteers
- 78 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder, Substance Abuse
Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder
The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.
- Trial name
- NCT00399763
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Adult Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT01692782
- Testing
- SEP-225289
- Where
- 31 sites in United States
- Volunteers
- 341 people
- Sponsor
- Sumitomo Pharma America, Inc.
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics